Humacyte, Inc.
12
1
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
25%
3 trials in Phase 3/4
38%
3 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
Role: lead
Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access
Role: lead
Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries
Role: lead
Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
Role: lead
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
Role: lead
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Role: lead
An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma
Role: lead
Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PAD
Role: lead
Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD
Role: lead
Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis
Role: lead
Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma
Role: lead
Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
Role: lead
All 12 trials loaded